Literature DB >> 8172940

Dopamine D1 receptor number--a sensitive PET marker for early brain degeneration in Huntington's disease.

G Sedvall1, P Karlsson, A Lundin, M Anvret, T Suhara, C Halldin, L Farde.   

Abstract

D1-dopamine receptor binding in the brain was determined by positron emission tomography (PET) in five patients with Huntington's disease, in one asymptomatic gene carrier and in five control subjects. [11C] SCH 23390 was used as the radioligand. Brain morphology was recorded by MRI. The patients who all had a mild to moderate functional impairment showed an almost 50% reduction of putamen volume as well as D1-dopamine receptor density as compared to the controls. The total D1-dopamine receptor number in the putamen was reduced by 75% in the patient group. A similar reduction was found for the caudate nucleus. The asymptomatic gene carrier had volume and density values in the lower range of the control subjects. In the frontal neocortex there also tended to be a reduced D1-dopamine receptor binding in the symptomatic patients. The results indicate that [11C] SCH 23390 binding in combination with MRI can be used as a sensitive marker for early brain degeneration in Huntington's disease. This marker may be useful to monitor the pathophysiological effect of the disease gene and also to follow therapeutic interventions aiming at preventing the degenerative process.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8172940     DOI: 10.1007/bf02191583

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  36 in total

1.  Alterations in dopaminergic receptors in Huntington's disease.

Authors:  T D Reisine; J Z Fields; L Z Stern; P C Johnson; E D Bird; H I Yamamura
Journal:  Life Sci       Date:  1977-10-15       Impact factor: 5.037

2.  A dopamine- and cyclic AMP-regulated phosphoprotein enriched in dopamine-innervated brain regions.

Authors:  S I Walaas; D W Aswad; P Greengard
Journal:  Nature       Date:  1983-01-06       Impact factor: 49.962

3.  An immunohistochemical investigation of the human neostriatum in Huntington's disease.

Authors:  S Goto; A Hirano; R R Rojas-Corona
Journal:  Ann Neurol       Date:  1989-03       Impact factor: 10.422

4.  Nigral dopamine type-1 receptors are reduced in Huntington's disease: a postmortem autoradiographic study using [3H]SCH 23390 and correlation with [3H]forskolin binding.

Authors:  F Filloux; M V Wagster; S Folstein; D L Price; J C Hedreen; T M Dawson; J K Wamsley
Journal:  Exp Neurol       Date:  1990-11       Impact factor: 5.330

5.  The measurement of abnormal movement: methods developed for Huntington's disease.

Authors:  S E Folstein; B Jensen; R J Leigh; M F Folstein
Journal:  Neurobehav Toxicol Teratol       Date:  1983 Nov-Dec

6.  Putamen volume reduction on magnetic resonance imaging exceeds caudate changes in mild Huntington's disease.

Authors:  G J Harris; G D Pearlson; C E Peyser; E H Aylward; J Roberts; P E Barta; G A Chase; S E Folstein
Journal:  Ann Neurol       Date:  1992-01       Impact factor: 10.422

7.  Neuropeptide Y, somatostatin, and reduced nicotinamide adenine dinucleotide phosphate diaphorase in the human striatum: a combined immunocytochemical and enzyme histochemical study.

Authors:  N W Kowall; R J Ferrante; M F Beal; E P Richardson; M V Sofroniew; A C Cuello; J B Martin
Journal:  Neuroscience       Date:  1987-03       Impact factor: 3.590

8.  Reduced regional cerebral blood flow in Huntington's disease studied by SPECT.

Authors:  S G Hasselbalch; G Oberg; S A Sørensen; A R Andersen; G Waldemar; J F Schmidt; K Fenger; O B Paulson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-11       Impact factor: 10.154

9.  The combined use of positron emission tomography and DNA polymorphisms for preclinical detection of Huntington's disease.

Authors:  M R Hayden; J Hewitt; A J Stoessl; C Clark; W Ammann; W R Martin
Journal:  Neurology       Date:  1987-09       Impact factor: 9.910

10.  Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington's disease.

Authors:  J C Mazziotta; M E Phelps; J J Pahl; S C Huang; L R Baxter; W H Riege; J M Hoffman; D E Kuhl; A B Lanto; J A Wapenski
Journal:  N Engl J Med       Date:  1987-02-12       Impact factor: 91.245

View more
  15 in total

1.  Decreased N-acetyl-aspartate/choline ratio and increased lactate in the frontal lobe of patients with Huntington's disease: a proton magnetic resonance spectroscopy study.

Authors:  L Harms; H Meierkord; G Timm; L Pfeiffer; A C Ludolph
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-01       Impact factor: 10.154

2.  Benzodiazepine receptor quantification in Huntington's disease with [(123)I]omazenil and SPECT.

Authors:  L H Pinborg; C Videbaek; S G Hasselbalch; S A Sørensen; A Wagner; O B Paulson; G M Knudsen
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-05       Impact factor: 10.154

3.  Three-dimensional visualization and quantification of the benzodiazepine receptor population within a living human brain using PET and MRI.

Authors:  S Pauli; G Sedvall
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1997       Impact factor: 5.270

Review 4.  Functional imaging in Huntington's disease.

Authors:  Jane S Paulsen
Journal:  Exp Neurol       Date:  2009-01-03       Impact factor: 5.330

5.  Dopamine modulates the susceptibility of striatal neurons to 3-nitropropionic acid in the rat model of Huntington's disease.

Authors:  D S Reynolds; R J Carter; A J Morton
Journal:  J Neurosci       Date:  1998-12-01       Impact factor: 6.167

6.  Obsessive-Compulsive Disorder Symptoms in Huntington's Disease: A Case Report.

Authors:  Juan Carlos Molano-Eslava; Angela Iragorri-Cucalón; Gonzalo Ucrós-Rodríguez; Carolina Bonilla-Jácome; Santiago Tovar-Perdomo; David V Herin; Luis Orozco-Cabal
Journal:  Rev Colomb Psiquiatr       Date:  2008-10-01

7.  Tetrabenazine is neuroprotective in Huntington's disease mice.

Authors:  Hongyu Wang; Xi Chen; Yuemei Li; Tie-Shan Tang; Ilya Bezprozvanny
Journal:  Mol Neurodegener       Date:  2010-04-26       Impact factor: 14.195

8.  Evaluation of SCH 39166 as PET ligand for central D1 dopamine receptor binding and occupancy in man.

Authors:  P Karlsson; G Sedvall; C Halldin; C G Swahn; L Farde
Journal:  Psychopharmacology (Berl)       Date:  1995-10       Impact factor: 4.530

9.  Dopaminergic signaling and striatal neurodegeneration in Huntington's disease.

Authors:  Tie-Shan Tang; Xi Chen; Jing Liu; Ilya Bezprozvanny
Journal:  J Neurosci       Date:  2007-07-25       Impact factor: 6.167

Review 10.  Neuroimaging in Huntington's disease.

Authors:  Flavia Niccolini; Marios Politis
Journal:  World J Radiol       Date:  2014-06-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.